Abstract
Nitric oxide is a potent vasodilator that plays a critical role in disorders of erythrocyte function. Sickle cell disease, paroxysmal nocturnal hemoglobinuria and banked blood preservation are three conditions where nitric oxide is intimately related to dysfunctional erythrocytes. These conditions are accompanied by hemolysis, thrombosis and vasoocclusion. Our understanding of the interaction between nitric oxide, hemoglobin, and the vasculature is constantly evolving, and by defining this role we can better direct trials aimed at improving the treatments of disorders of erythrocyte function. Here we briefly discuss nitric oxide’s interaction with hemoglobin through the hypothesis regarding Snitrosohemoglobin, deoxyhemoglobin, and myoglobin as nitrite reductases. We then review the current understanding of the role of nitric oxide in sickle cell disease, paroxysmal nocturnal hemoglobinuria, and banked blood, and discuss therapeutics in development to target nitric oxide in the treatment of some of these disorders.
Keywords: Banked blood, erythrocytes, hemoglobin, nitric oxide, nitrite reductase, sickle cell disease.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Updated Role of Nitric Oxide in Disorders of Erythrocyte Function
Volume: 13 Issue: 1
Author(s): Marc J. Kahn, Jason H. Maley, George F. Lasker and Philip J. Kadowitz
Affiliation:
Keywords: Banked blood, erythrocytes, hemoglobin, nitric oxide, nitrite reductase, sickle cell disease.
Abstract: Nitric oxide is a potent vasodilator that plays a critical role in disorders of erythrocyte function. Sickle cell disease, paroxysmal nocturnal hemoglobinuria and banked blood preservation are three conditions where nitric oxide is intimately related to dysfunctional erythrocytes. These conditions are accompanied by hemolysis, thrombosis and vasoocclusion. Our understanding of the interaction between nitric oxide, hemoglobin, and the vasculature is constantly evolving, and by defining this role we can better direct trials aimed at improving the treatments of disorders of erythrocyte function. Here we briefly discuss nitric oxide’s interaction with hemoglobin through the hypothesis regarding Snitrosohemoglobin, deoxyhemoglobin, and myoglobin as nitrite reductases. We then review the current understanding of the role of nitric oxide in sickle cell disease, paroxysmal nocturnal hemoglobinuria, and banked blood, and discuss therapeutics in development to target nitric oxide in the treatment of some of these disorders.
Export Options
About this article
Cite this article as:
Kahn J. Marc, Maley H. Jason, Lasker F. George and Kadowitz J. Philip, Updated Role of Nitric Oxide in Disorders of Erythrocyte Function, Cardiovascular & Hematological Disorders-Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/1871529X11313010009
DOI https://dx.doi.org/10.2174/1871529X11313010009 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gender and Cardiovascular Mortality in Northern and Southern European Populations
Current Pharmaceutical Design Glycogen Synthase Kinase-β3 in Ischemic Neuronal Death
Current Neurovascular Research New Inotropic Pharmacologic Strategies Targeting the Failing Myocardiumin the Newborn and Infant
Mini-Reviews in Medicinal Chemistry Protective Effects of Anesthetics on Vascular Function Related to K<sup>+</sup> Channels
Current Pharmaceutical Design New Perspectives on Acetaminophen
Current Cardiology Reviews Insights into the Pathogenesis and Intervention of Atherosclerosis
Vascular Disease Prevention (Discontinued) Anesthetic and Adjunctive Drugs for Fast-Track Surgery
Current Drug Targets Intracoronary Injection of Glycoprotein IIb/IIIa, Abciximab, as Adjuvant Therapy in Primary Coronary Intervention
Cardiovascular & Hematological Agents in Medicinal Chemistry Hydrophilic Dual Vitamin E-Like Antioxidants as Modulators of Inflammatory Response in Low-Flow States and Impaired Wound Healing
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results
Current Medicinal Chemistry Pathological Roles of Iron in Cardiovascular Disease
Current Drug Targets Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions
Current Drug Metabolism Memory Impairment is Associated with Serum Methylarginines in Older Adults
Current Alzheimer Research Effects of Endothelins on Cardiac and Vascular Cells: New Therapeutic Target for the Future?
Current Vascular Pharmacology Midkine in Inflammatory and Toxic Conditions
Current Drug Delivery Stem Cell Aging and Age-Related Cardiovascular Disease: Perspectives of Treatment by Ex-vivo Stem Cell Rejuvenation
Current Drug Targets Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease
Current Pharmaceutical Design New Insight into the Mechanisms of <i>Ginkgo Biloba</i> Extract in Vascular Aging Prevention
Current Vascular Pharmacology Matrix Metalloproteinases as Drug Targets in Acute Pulmonary Embolism
Current Drug Targets Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design